Anti-tumor necrosis factor α treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis.

[1]  P. Calzavara-Pinton,et al.  C-Reactive Protein and Markers for Thrombophilia in Patients with Chronic Plaque Psoriasis , 2010, International journal of immunopathology and pharmacology.

[2]  A. Coats,et al.  Ethics in the authorship and publishing of scientific articles , 2010 .

[3]  J. Prinz,et al.  From bench to bedside – translational research in psoriasis , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  P. Tak,et al.  Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo , 2010, PloS one.

[5]  D. Gladman,et al.  Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT , 2010, Arthritis research & therapy.

[6]  P. Ridker.  Psoriasis, inflammation, and vascular risk: a problem more than skin deep? , 2010, European heart journal.

[7]  Petros P Sfikakis,et al.  The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. , 2010, Current directions in autoimmunity.

[8]  A. Levine,et al.  IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells1 , 2009, The Journal of Immunology.

[9]  A. Zwinderman,et al.  A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue , 2008, Annals of the rheumatic diseases.

[10]  A. Kimball,et al.  Impact of adalimumab treatment on patient‐reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis , 2007, The Journal of dermatological treatment.

[11]  R. Shikiar,et al.  Adalimumab treatment is associated with improvement in health‐related quality of life in psoriasis: Patient‐reported outcomes from a Phase II randomized controlled trial , 2007, The Journal of dermatological treatment.

[12]  R. Kirsner,et al.  Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. , 2005, Journal of the American Academy of Dermatology.

[13]  R. Merendino,et al.  Serum levels of interleukin‐18 and s‐ICAM‐1 in patients affected by psoriasis: preliminary considerations , 2003, Journal of the European Academy of Dermatology and Venereology : JEADV.